CTIS2024-513141-37-00进行中（未招募）1 期
Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease. - ChIm-NB-P
niwersytet Jagiellonski Collegium Medicum0 个研究点目标入组 28 人开始时间: 2024年3月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- All
入选标准
- •Diagnosis of NBL according to international criteria (International Neuroblastoma Risk Group, INRG)., Patients 1-18 years of age with HR-NBL with primary refractory disease, disease progression or recurrence., Adequate function of vital organs (if abnormal, dysfunction below grade 4 according to the CTC AE WHO classification, except for disorders defined in the exclusion criteria)., Life expectancy =6 months.
排除标准
- •Patients with toxicities of =3 CTCAE WHO grade, except hearing impairment, hematological disorders, liver and kidney disorders., Patients with neurological toxicities of =2 CTCAE WHO grade., Active life-threatening infection until stabilization of the patient's condition., Pregnancy and / or lactation, Radiotherapy within 3 weeks prior to the start of the study.
研究者
相似试验
进行中（未招募）
1 期
Combination therapy with anti-GD2 antibody immunotherapy (dinutuximab beta) in combination with chemotherapy for refractory neuroblastomaRecurrent or progression of neuroblastoma or neuroblastoma refractory to first-line treatmentMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10066595Term: Neuroblastoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10029261Term: Neuroblastoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003832-96-PLJagiellonian University Medical College20
进行中（未招募）
1 期
Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastomaCTIS2023-509673-22-00Prinses Maxima Centrum voor Kinderoncologie B.V.8
招募中
1 期
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in NeuroblastomaNeuroblastomaNCT06485947Princess Maxima Center for Pediatric Oncology38
招募中
1 期
Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive DiseaseHigh-Risk NeuroblastomaNCT05272371Jagiellonian University20
已完成
2 期
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With LeiomyosarcomaLeiomyosarcomaNCT05080790Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest7